Screening and management of cardiovascular disease in Australian adults with HIV infection
Derek Chan A F , David Gracey B , Michael Bailey C , Deborah Richards D and Brad Dalton E
+ Author Affiliations
- Author Affiliations
A Albion Centre, Sydney, NSW 2010, Australia.
B Renal Unit, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
C Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Vic. 3800, Australia.
D Gilead Sciences Pty Ltd, Melbourne, Vic. 3004, Australia.
E School of Human Life Sciences, University of Tasmania, Launceston, Tas. 7248, Australia.
F Corresponding author. Email: Derek.Chan2@sesiahs.health.nsw.gov.au
Submitted: 28 August 2012 Accepted: 1 August 2013 Published: 25 October 2013
Abstract
Background: Cardiovascular disease (CVD) is common in HIV infection. With no specific Australian guidelines for the screening and management of CVD in HIV-infected patients, best clinical practice is based on data from the general population. We evaluated adherence to these recommendations by primary care physicians who treat HIV-infected patients. Methods: Primary care physicians with a special interest in HIV infection were asked to complete details for at least 10 consecutive patient encounters using structured online forms. This included management practices pertaining to blood pressure (BP), blood glucose, electrocardiogram, lipid profile and CVD risk calculations. We assessed overall adherence to screening and follow-up recommendations as suggested by national and international guidelines. Results: Between May 2009 and March 2010, 43 physicians from 25 centres completed reporting for 530 HIV-infected patients, of whom 93% were male, 25% were aged 41–50 years and 83% were treated with antiretrovirals. Risk factors for CVD were common and included smoking (38%), hyperlipidaemia (16%) and hypertension (28%). In men aged >40 years and women aged >50 years without evidence of ischaemic heart disease, only 14% received a CVD risk assessment. Lipid and BP assessments were performed in 87% and 88% of patients, respectively. Conclusions: This Australian audit provides unique information on the characteristics and management of HIV and CVD in clinical practice. We have found a high burden of risk for CVD in HIV-infected Australians, but current screening and management practices in these patients fall short of contemporary guidelines.
Additional keywords: blood pressure, guidelines, lipids, risk factors.
References
[1] d’Arminio Monforte A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, et al Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18 1811–7.| Cardio- and cerebrovascular events in HIV-infected persons.Crossref | GoogleScholarGoogle Scholar |
[2] Friis-Møller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349 1993–2003.
| Combination antiretroviral therapy and the risk of myocardial infarction.Crossref | GoogleScholarGoogle Scholar | 14627784PubMed |
[3] Friis-Møller N, Thiebaut R, Reiss P, Weber R, d’Arminio Monforte A, De Wit S, et al Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17 491–501.
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.Crossref | GoogleScholarGoogle Scholar | 20543702PubMed |
[4] Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, d’Arminio Monforte A, et al Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17 1179–93.
| Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study.Crossref | GoogleScholarGoogle Scholar | 12819520PubMed |
[5] Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53 10–4.
| Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3sXhtVShsb3M&md5=a805a8f428851a9f68531b27b2e1dc79CAS | 14645323PubMed |
[6] Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12 F51–8.
| A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK1c3otFSqtQ%3D%3D&md5=3c587694c3495a681ff91257b4175cc5CAS | 9619798PubMed |
[7] Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351 1881–3.
| Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK1cXksVSmt7o%3D&md5=501a67ea94b3fe4732aa3203a9dfded4CAS | 9652687PubMed |
[8] Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86 27–31.
| Hypertriglyceridemia in the acquired immunodeficiency syndrome.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaL1M%2Fos1Clsg%3D%3D&md5=d84e0ab134e0138c809d841e0d050de0CAS | 2910092PubMed |
[9] Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74 1045–52.
| Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK383jsFaisg%3D%3D&md5=b918f7308be88ec6d5b667b4ff89a310CAS | 1373735PubMed |
[10] Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O’Shaughnessy MV, et al Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15 231–9.
| Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3M3isV2jtA%3D%3D&md5=f1d928744338f7d9be602995e8e8c135CAS | 11216932PubMed |
[11] Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991; 40 651–6.
| Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK3MzisF2gsg%3D%3D&md5=df14d86bc4aa36c2566556c444a086ebCAS | 1865829PubMed |
[12] Déti EK, Thiebaut R, Bonnet F, Lawson-Ayayi S, Dupon M, Neau D, et al Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med 2010; 11 308–17.
| Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.Crossref | GoogleScholarGoogle Scholar | 20002500PubMed |
[13] Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol 2009; 5 563–73.
| The nephrotoxic effects of HAART.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXhtFOiu7jI&md5=f76148f934c6c1c036eca1c0747534f0CAS | 19776778PubMed |
[14] Australian Institute of Health and Welfare (AIHW). Australia’s health 2008. Canberra: AIHW; 2008.
[15] National Heart Foundation of Australia (NHF), Cardiac Society of Australia and New Zealand (CSANZ). Reducing risk in heart disease 2007: guidelines for prevention cardiovascular events in people with coronary heart disease. Canberra: NHF and CSANZ; 2008. Available online at: http://www.heartfoundation.org.au/SiteCollectionDocuments/Reduce-risk-in-heart-disease-guideline.pdf [verified May 2010].
[16] National Heart Foundation of Australia (NHF), Cardiac Society of Australia and New Zealand (CSANZ). Guide to management of hypertension 2008: assessing and managing raised blood pressure in adults. Canberra: NHF and CSANZ; 2009. Available online at: http://www.heartfoundation.org.au/SiteCollectionDocuments/HypertensionGuidelines2008to2010Update.pdf [verified May 2010].
[17] Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, et al European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9 72–81.
| European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXjsl2lur8%3D&md5=d19b31e88d7fdb2f1d01edd9942b8a04CAS | 18257770PubMed |
[18] Kemp TM, Barr EL, Zimmet PZ, Cameron AJ, Welborn TA, Colagiuri S, et al Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999–2000 AusDiab. Diabetes Care 2005; 28 1490–2.
| Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999–2000 AusDiab.Crossref | GoogleScholarGoogle Scholar | 15920075PubMed |
[19] Vale MJ, Jelinek MV, Best JD. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996–1998 versus 1999–2000. Med J Aust 2002; 176 211–5.
| 11999236PubMed |
[20] Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannel WB. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol 1989; 130 469–80.
| 1:STN:280:DyaL1MzkvFWmtw%3D%3D&md5=ef729327e2487a7371a9fba676e90e18CAS | 2763992PubMed |
[21] Yong TY, Phillipov G, Phillips PJ. Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease. Med J Aust 2007; 186 622–4.
| 17576176PubMed |
[22] Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27 1535–40.
| The burden of treatment failure in type 2 diabetes.Crossref | GoogleScholarGoogle Scholar | 15220224PubMed |
[23] Davis TM, Davis WA, Bruce DG. Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. Med J Aust 2006; 184 325–8.
| 16584365PubMed |
[24] LaBresh KA, Fonarow GC, Smith SC, Bonow RO, Smaha LC, Tyler PA, et al Improved treatment of hospitalized coronary artery disease patients with the Get with the Guidelines program. Crit Pathw Cardiol 2007; 6 98–105.
| Improved treatment of hospitalized coronary artery disease patients with the Get with the Guidelines program.Crossref | GoogleScholarGoogle Scholar | 17804969PubMed |
[25] The Royal Australian College of General Practitioners (RACGP). Quality Improvement & Continuing Professional Development Program 2011–2013 2011–2013 Triennium Handbook. Melbourne: RACGP; 2010. Available online at: http://qicpd.racgp.org.au/media/39262/qicpd-program-handbook-2010-locked.pdf [verified 20 September 2013].
[26] National Centre in HIV Epidemiology and Clinical Research (NCHECR). Australian HIV observational database annual report. Sydney: NCHECR; 2010.
[27] Mallewa JE, Higgins SP, Garbett S, Saxena N, Vilar FJ. Cardiovascular disease risk management in HIV patients, experiences from Greater Manchester. Int J STD AIDS 2009; 20 425–6.
| Cardiovascular disease risk management in HIV patients, experiences from Greater Manchester.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD1MzltlyltA%3D%3D&md5=132815a40e11c576830e2fb0636a0e20CAS | 19451331PubMed |
[28] Petoumenos K, Worm S, Reiss P, de Wit S, d’Arminio Monforte A, Sabin C, et al Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med 2011; 12 412–21.
| Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC3MjnsVGksA%3D%3D&md5=68402520d80c577ef90ba457a6a28519CAS | 21251183PubMed |
[29] Webster RJ, Heeley EL, Peiris DP, Bayram C, Cass A, Patel AA. Gaps in cardiovascular disease risk management in Australian general practice. Med J Aust 2009; 191 324–9.
| 19769555PubMed |
[30] National Vascular Disease Prevention Alliance (NVDPA). Guidelines for the assessment of absolute cardiovascular disease risk. Melbourne: NVDPA; 2009.
[31] D:A:D Study Group. 5 year estimated risk calculator. Copenhagen: Copenhagen HIV Programme.; 2011. Available online at: http://www.cphiv.dk/tools/dadriskequations/tabid/437/default.aspx [verified January 2013].
[32] Hall LM, Jung RT, Leese GP. Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ 2003; 326 251–2.
| Controlled trial of effect of documented cardiovascular risk scores on prescribing.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3s%2FkvFCitA%3D%3D&md5=9810a2ee776dea97de553eb88a193f38CAS | 12560273PubMed |
[33] Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover S. Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS). Prev Med 1998; 27 730–7.
| Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS).Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK1M%2FjtVGntQ%3D%3D&md5=86a78519dd8adb477a181d690efb14efCAS | 9808805PubMed |
[34] Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152 56–64.
| Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK387gt1ejsw%3D%3D&md5=bb3d78736865df26332cc1248c04408cCAS | 1728930PubMed |
[35] Heeley EL, Peiris DP, Patel AA, Cass A, Weekes A, Morgan C, et al Cardiovascular risk perception and evidence–practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010; 192 254–9.
| 20201758PubMed |
